Search academic texts

Information × Registration Number 0213U004033, 0110U001061 , R & D reports Title To define the pharmacogenetics factors a chronic heart failure and to develop the differential pharmacotherapy of a disease. popup.stage_title Head Yu. Rudyk, Registration Date 24-01-2013 Organization Government institution "L.T. Malaya Therapy Institute National Academy of Medical Sciences of Ukraine" popup.description2 The 264 patients with heart failure (HF). The methods are clinically, genetic-biochemistry, instrumental. The frequencies of common types of gene polymorphisms 1- and 2-adrenergic receptors (AR) and their haplotypes in patients with HF. The connection of the combined gene haplotypes В1- and В2-AR. Most adverse of them are Ser49Ser/Gly389Gly-Gln27Gln and Ser49Ser/Gly389Gly-Glu27Gln. Sick of these groups have a negative trend in LVEF and left atrial diameter, poor the chronotropic response to the use of bisoprolol, a higher frequency of atrial fibrillation, the highest rate of hospitalizations due to decompensated disease. These patients are the best use of the defendants in the carvedilol. In patients with heart failure who have a combined polymorphisms and Ser49Ser/Gly389Gly-Gln27Gln Ser49Ser/Gly389Gly-Glu27Gln need to assign a carvedilol, an amiodarone and a spironolactone. Product Description popup.authors Алексєєва М.О. Болотських Г.В. Кравченко І.Г. Лозік Т.В. Мухіна О.К. Пивовар С.М. Рудик Ю.С. Удовиченко М.М. popup.nrat_date 2020-04-02 Close